Daniel MBA - ProMIS Neurosciences Chief Officer
| PMN Stock | USD 1.01 0.04 4.12% |
Executive
Daniel MBA is Chief Officer of ProMIS Neurosciences
| Age | 67 |
| Address | 1920 Yonge Street, Toronto, ON, Canada, M4S 3E2 |
| Phone | 416 847 6898 |
| Web | https://www.promisneurosciences.com |
ProMIS Neurosciences Management Efficiency
The company has Return on Asset of (4.8073) % which means that on every $100 spent on assets, it lost $4.8073. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (10.9851) %, meaning that it generated no profit with money invested by stockholders. ProMIS Neurosciences' management efficiency ratios could be used to measure how well ProMIS Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to drop to -1.02. In addition to that, Return On Capital Employed is likely to drop to -3.51. At this time, ProMIS Neurosciences' Total Assets are very stable compared to the past year. As of the 11th of December 2024, Other Assets is likely to grow to 1.21, while Non Current Assets Total are likely to drop about 24.5 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| HansPeter Gerber | Sutro Biopharma | 61 | |
| Alice PharmD | Inventiva Sa | 53 | |
| Marc MD | NewAmsterdam Pharma | 57 | |
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| Lucinda Warren | Cue Biopharma | N/A | |
| Jonas MD | Gain Therapeutics | N/A | |
| Nathalie Harroy | Inventiva Sa | 57 | |
| Sarika Gulhar | Opthea | N/A | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| Barbara Leyman | Sutro Biopharma | N/A | |
| David Socks | Hillevax | 49 | |
| Sheng Cui | NewAmsterdam Pharma | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Clarence Ahlem | Biovie Inc | 69 | |
| Marc MD | NewAmsterdam Pharma | 57 | |
| MBA Jones | NewAmsterdam Pharma | 60 | |
| Minori MD | Compass Therapeutics | 61 | |
| Matteo MD | Cue Biopharma | 55 | |
| Bob Rambo | NewAmsterdam Pharma | N/A | |
| Terry Evans | Fennec Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -10.99 | ||||
| Return On Asset | -4.81 |
ProMIS Neurosciences Leadership Team
Elected by the shareholders, the ProMIS Neurosciences' board of directors comprises two types of representatives: ProMIS Neurosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProMIS. The board's role is to monitor ProMIS Neurosciences' management team and ensure that shareholders' interests are well served. ProMIS Neurosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProMIS Neurosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gail Farfel, Chief Officer | ||
| Daniel MBA, Chief Officer | ||
| Johanne Kaplan, Chief Officer | ||
| Dennis Chen, Head Consultant | ||
| Neil MD, CoChairman CoFounder | ||
| Eugene Williams, CoFounder Chairman | ||
| David Wishart, Chief Officer | ||
| Neil MBA, Interim President | ||
| MBA MBA, Chief Officer | ||
| Gavin Malenfant, Chief Officer | ||
| Ernest Bush, Head Consultant | ||
| Larry MD, Chief Officer |
ProMIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ProMIS Neurosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.99 | ||||
| Return On Asset | -4.81 | ||||
| Current Valuation | 10.11 M | ||||
| Shares Outstanding | 32.69 M | ||||
| Shares Owned By Insiders | 44.78 % | ||||
| Shares Owned By Institutions | 50.30 % | ||||
| Number Of Shares Shorted | 200.13 K | ||||
| Price To Book | 4.36 X | ||||
| Price To Sales | 5,168 X | ||||
| Gross Profit | (16.09 M) |
Pair Trading with ProMIS Neurosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with ProMIS Stock
Moving against ProMIS Stock
| 0.78 | BMY | Bristol Myers Squibb | PairCorr |
| 0.72 | GILD | Gilead Sciences | PairCorr |
| 0.7 | ESPR | Esperion Therapeutics | PairCorr |
| 0.47 | FLGC | Flora Growth Corp | PairCorr |
| 0.47 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.